Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03599362 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03599362 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 7 participants.
The verdict
NCT03599362, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic body radiotherapy (SBRT) in patients with LAUPC. The purpose of this study is to determine the safety and tolerability of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer. Investigators will also estimate the surgical resection rate following treatment with combined cabiralizumab, nivolumab and radiotherapy in subjects with locally advanced unresectable pancreatic cancer.
Interventions
- RADIATION Stereotactic Body Radiotherapy (SBRT)
- DRUG Nivolumab + Cabiralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2020-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03599362
The ClinicalTrials.gov registry entry for NCT03599362 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiotherapy (SBRT) is the first listed.
NCT03599362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03599362 about?
NCT03599362 is a clinical study titled "Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer". A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic body radiotherapy (SBRT) in patients with LAUPC. The purpose of this study is to determine the safety and tolerability of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advan...
What is the current status of trial NCT03599362?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2018-07-31. Estimated completion is 2020-06-15.
What interventions are being tested in trial NCT03599362?
The interventions under investigation include: Stereotactic Body Radiotherapy (SBRT) (RADIATION), Nivolumab + Cabiralizumab (DRUG).
Who is sponsoring clinical trial NCT03599362?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.